Serum galectin-3 and aldosterone : potential biomarkers of cardiac complications in patients with COVID-19
BACKGROUND: Despite severe acute respiratory syndrome (SARS)-Coronavirus (CoV-2) primarily targeting the lungs, the heart represents another critical virus target. Thus, the identification of SARS-CoV-2 disease of 2019 (COVID-19)-associated biomarkers would be beneficial to stratify prognosis and the risk of developing cardiac complications. Aldosterone and galectin-3 promote fibrosis and inflammation and are considered a prognostic biomarker of lung and adverse cardiac remodeling. Here, we tested whether galectin-3 and aldosterone levels can predict adverse cardiac outcomes in COVID-19 patients.
METHODS: To this aim, we assessed galectin-3 and aldosterone serum levels in 51 patients diagnosed with COVID-19, using a population of 19 healthy subjects as controls. In in-vitro studies, we employed 3T3 fibroblasts to assess the potential roles of aldosterone and galectin-3 in fibroblast activation.
RESULTS: Serum galectin-3 levels were more elevated in COVID-19 patients than healthy controls and correlated with COVID-19 severity classification and cardiac troponin-I (cTnI) serum levels. Furthermore, we observed an augmented secretion of aldosterone in COVID-19 patients. This adrenal hormone is a direct stimulator of galectin-3 secretion; therefore, we surmised that this axis could perpetrate fibrosis and adverse remodeling in these subjects. Thus, we stimulated fibroblasts with 10% of serum from COVID-19 patients. This challenge markedly rose the expression of smooth muscle alpha (α)-2 actin (ACTA2), a myofibroblast marker.
CONCLUSIONS: Our study suggests that COVID-19 can affect cardiac structure and function by triggering aldosterone and galectin-3 release that may serve as prognostic and therapeutic biomarkers while monitoring the course of cardiac complications in patients suffering from COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Minerva endocrinology - 47(2022), 3 vom: 10. Sept., Seite 270-278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cannavo, Alessandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4964P6T9RB |
|---|
| Anmerkungen: |
Date Completed 03.10.2022 Date Revised 05.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.23736/S2724-6507.22.03789-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337975396 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337975396 | ||
| 003 | DE-627 | ||
| 005 | 20231225235630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23736/S2724-6507.22.03789-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337975396 | ||
| 035 | |a (NLM)35266671 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cannavo, Alessandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum galectin-3 and aldosterone |b potential biomarkers of cardiac complications in patients with COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.10.2022 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Despite severe acute respiratory syndrome (SARS)-Coronavirus (CoV-2) primarily targeting the lungs, the heart represents another critical virus target. Thus, the identification of SARS-CoV-2 disease of 2019 (COVID-19)-associated biomarkers would be beneficial to stratify prognosis and the risk of developing cardiac complications. Aldosterone and galectin-3 promote fibrosis and inflammation and are considered a prognostic biomarker of lung and adverse cardiac remodeling. Here, we tested whether galectin-3 and aldosterone levels can predict adverse cardiac outcomes in COVID-19 patients | ||
| 520 | |a METHODS: To this aim, we assessed galectin-3 and aldosterone serum levels in 51 patients diagnosed with COVID-19, using a population of 19 healthy subjects as controls. In in-vitro studies, we employed 3T3 fibroblasts to assess the potential roles of aldosterone and galectin-3 in fibroblast activation | ||
| 520 | |a RESULTS: Serum galectin-3 levels were more elevated in COVID-19 patients than healthy controls and correlated with COVID-19 severity classification and cardiac troponin-I (cTnI) serum levels. Furthermore, we observed an augmented secretion of aldosterone in COVID-19 patients. This adrenal hormone is a direct stimulator of galectin-3 secretion; therefore, we surmised that this axis could perpetrate fibrosis and adverse remodeling in these subjects. Thus, we stimulated fibroblasts with 10% of serum from COVID-19 patients. This challenge markedly rose the expression of smooth muscle alpha (α)-2 actin (ACTA2), a myofibroblast marker | ||
| 520 | |a CONCLUSIONS: Our study suggests that COVID-19 can affect cardiac structure and function by triggering aldosterone and galectin-3 release that may serve as prognostic and therapeutic biomarkers while monitoring the course of cardiac complications in patients suffering from COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Actins |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Galectin 3 |2 NLM | |
| 650 | 7 | |a Troponin I |2 NLM | |
| 650 | 7 | |a Aldosterone |2 NLM | |
| 650 | 7 | |a 4964P6T9RB |2 NLM | |
| 700 | 1 | |a Liccardo, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Gelzo, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Amato, Felice |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Pinchera, Biagio |e verfasserin |4 aut | |
| 700 | 1 | |a Femminella, Grazia D |e verfasserin |4 aut | |
| 700 | 1 | |a Parrella, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a DE Rosa, Annunziata |e verfasserin |4 aut | |
| 700 | 1 | |a Gambino, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Marzano, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Paolocci, Nazareno |e verfasserin |4 aut | |
| 700 | 1 | |a Rengo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Castaldo, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Minerva endocrinology |d 2021 |g 47(2022), 3 vom: 10. Sept., Seite 270-278 |w (DE-627)NLM309915252 |x 2724-6116 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2022 |g number:3 |g day:10 |g month:09 |g pages:270-278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23736/S2724-6507.22.03789-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2022 |e 3 |b 10 |c 09 |h 270-278 | ||